Do TRPM6 variants increase susceptibility to hypomagnesemia by impairing intestinal and renal magnesium transport?

Genetic variants in the TRPM6 gene are well-established drivers of magnesium deficiency through their dual impact on the primary regulatory checkpoints of magnesium homeostasis: the small intestine and the distal convoluted tubule of the kidney.

Clinical evidence and impact on magnesium status

Genetic disruption of TRPM6 leads to significant clinical manifestations of hypomagnesemia.

• Monogenic disorders: Loss-of-function mutations in TRPM6 (such as c.3308dupC or c.3958C>T) are the causal factor for Primary Hypomagnesemia with Secondary Hypocalcemia (HSH or HOMG1). Patients with these biallelic mutations present with profound serum magnesium levels (often <0.3 mmol/L) and secondary deficiencies in calcium.
• Common polymorphisms: Beyond rare mutations, common variants like rs2274924 (A>G; Lys1579Glu) influence magnesium susceptibility in the general population. Research indicates that the G allele (CT/CC genotypes) is associated with an increased prevalence of hypomagnesemia, particularly in populations with existing inflammatory stress, such as those with rheumatoid arthritis.
• Metabolic associations: The rs2274924 variant has been linked to an increased risk of type 2 and gestational diabetes when dietary magnesium intake is low (<250 mg/day), suggesting these variants impair the body's ability to maintain homeostasis under suboptimal nutritional conditions.

Mechanistic explanations

TRPM6 acts as a unique "chanzyme," combining a magnesium-permeable ion channel with a protein kinase domain. It is the gatekeeper for active, transcellular magnesium transport.

• Intestinal absorption: TRPM6 is localized to the apical membrane of enterocytes (primarily in the duodenum and cecum). While most magnesium is absorbed passively, TRPM6 is the critical mechanism for active uptake against electrochemical gradients. Intestine-specific TRPM6 knockout models demonstrate that losing this channel significantly impairs 25Mg2+ uptake, leading to systemic deficiency.
• Renal reabsorption: In the kidney, TRPM6 is found in the distal convoluted tubule (DCT). It facilitates the "fine-tuning" of magnesium reabsorption. Genetic variants disrupt this by either abolishing the channel's conductance or preventing it from forming functional heteromeric complexes with its partner, TRPM7.
• Renal wasting: This disruption manifests as renal magnesium wasting, where patients exhibit inappropriately high fractional excretion of magnesium (FE_Mg > 2–4%) despite critically low blood levels.

Bottom line

Genetic variants in TRPM6 directly increase susceptibility to hypomagnesemia by impairing active magnesium uptake in the intestines and preventing efficient reabsorption in the kidneys. For individuals with these variants, maintaining higher-than-average dietary magnesium intake may be necessary to compensate for reduced transport efficiency.